Marker Therapeutics, Inc. (MRKR) News
Filter MRKR News Items
MRKR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRKR News Highlights
- MRKR's 30 day story count now stands at 2.
- Over the past 10 days, the trend for MRKR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MRKR are DEC and MT.
Latest MRKR News From Around the Web
Below are the latest news stories about MARKER THERAPEUTICS INC that investors may wish to consider to help them evaluate MRKR as an investment opportunity.
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that the Company’s management team will participate in Biotech Showcase and present at the 19th Annual Non-Dilutive Funding Summit. Both events will be held in-person and are scheduled alongside the J.P. Morgan 42 |
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseStudy participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and remains in complete response six months after MT-601 treatmentHOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported a clinical update on |
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesAnnounced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (zedenoleucel) for the treatment of patients with Acute Myeloid Leukemia (AML) Demonstrated enhanced anti-tumor activity in an aggressive, treatment-resistant AML cell line and provided an update on clinical readiness of the MT-401 Off-the-She |
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceHOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Pala |
Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to OutperformanceUnraveling the Evolving Narrative of Marker Therapeutics Inc |
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell TherapiesCranford, New Jersey--(Newsfile Corp. - August 17, 2023) - Marker Therapeutics (NASDAQ: MRKR) highlights its technology during a recently held, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient's own T cells to fight cancer. To view the full announcement, including downloadable ... |
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateExecuted comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive Officer and Monic Stuart, M.D., MPH, as Chief Medical Officer to spearhead Marker’s restructuring efforts and guide clinical advancement of Marker’s multiTAA-specific T cell technology Announced encouraging non-clinical data from MT-401 program demonstrating increased anti-tumor activity against an ac |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start Wednesday with an overview of all the biggest pre-market stock movers traders need to know about this morning! |
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf ProgramHOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced non-clinical data of its lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, in an Off-the-Shelf (OTS) setting and provided an update on clinical readiness for the OTS program |